(NASDAQ: TRAW) Traws Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.67%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Traws Pharma's earnings in 2026 is $6,865,000.On average, 4 Wall Street analysts forecast TRAW's earnings for 2026 to be -$27,097,530, with the lowest TRAW earnings forecast at -$29,175,705, and the highest TRAW earnings forecast at -$24,529,776. On average, 4 Wall Street analysts forecast TRAW's earnings for 2027 to be -$22,709,595, with the lowest TRAW earnings forecast at -$30,797,819, and the highest TRAW earnings forecast at -$13,758,005.
In 2028, TRAW is forecast to generate -$7,148,677 in earnings, with the lowest earnings forecast at -$6,868,337 and the highest earnings forecast at -$7,358,933.